ChroMedX Announces Exercise of Warrants

Toronto, Ontario--(December 13, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that since November 2017 investors have exercised warrants to acquire 1,031,000 new common shares of the Company as of December 12, 2017.

The total consideration received was CAD$226,200. The Warrant Shares will rank pari passu in all respects with the existing common shares of the Company.